Dublin, May 04, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Apixaban Market 2021-2025" report has been added to ResearchAndMarkets.com's offering.
The sales revenue of Apixaban in China has been increasing from 2016 to 2020, and it has reached approximately CNY 29.32 million in 2020, with a CAGR of 42% from 2016 to 2020.
As a major country for cardiovascular and cerebrovascular diseases, along with the promotion and popularization of anticoagulation concepts, China is expected to gradually increase the market share of Apixaban from 2021 to 2025, and the sales value and volume will both increase accordingly.
Anticoagulation therapy plays an important role in the prevention and treatment of thromboembolic diseases. The two most famous drugs are Rivaroxaban and Apixaban, mainly used to prevent and treat venous thrombosis, and prevent systemic embolism caused by atrial fibrillation. Due to Apixaban's excellent safety performance, its market has grown rapidly since 2014, and surpassed Rivaroxaban's in 2017 to become the world's best-selling anticoagulant drug.
Apixaban was launched in China in 2013. The original drug is ELIQUIS produced by Bristol-Myers Squibb Co/Pfizer EEIG. The sales growth of Apixaban mainly depends on the growth of the antithrombotic industry. While other countries' Apixaban markets account for large shares among the whole pharmaceutical markets.
The Chinese Apixaban market share is much lower. The main reason is that the Chinese medical system does not recognize the importance of anticoagulation as the developed countries do.
Topics Covered:
- The impact of COVID-19 on China's apixaban market
- Sales value and volume of China's apixaban 2016-2020
- Competitive landscape of China's apixaban market
- Prices of apixaban in China
- Prices of apixaban in China by regions and manufacturers
- Analysis of factors affecting the development of China's apixaban market
- Prospect of China's apixaban market from 2021 to 2025
Key Topics Covered:
1 Relevant Concepts of Apixaban
1.1 Indications for Apixaban
1.2 Development of Apixaban in China
1.3 Governmental Approval of Apixaban in China
1.4 The Impact of COVID-19 on Apixaban sales in China
2 Sales of Apixaban in China, 2016-2020
2.1 Sales Value of Apixaban
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Apixaban
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Apixaban by Dosage Form in China, 2016-2020
2.3.1 Tablet
2.3.2 Analysis of Other Dosage Forms
3 Analysis of Major Apixaban Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Apixaban Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Bristol-Myers Squibb Co/Pfizer EEIG
3.2.1 Enterprise Profile
3.2.2 Sales of ELIQUIS (Bristol-Myers Squibb/ Pfizer's Apixaban) in China
3.3 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of Anbeining (CTTQ's Apixaban) in China
3.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Zexin (Hansoh's Apixaban) in China
3.5 Sichuan Kelun Pharmaceutical Co., Ltd.
3.5.1 Enterprise Profile
3.5.2 Sales of Pukesha (Kelun's Apixaban) in China
3.6 Jiangsu Sinobiopharma Co., Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Yipaiping (Sinobiopharma's Apixaban) in China
4 Prices of Apixaban for Different Manufacturers in China, 2020-2021
4.1 Bristol-Myers Squibb Co/Pfizer EEIG (ELIQUIS)
4.2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Anbeining)
4.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (Zexin)
4.4 Sichuan Kelun Pharmaceutical Co., Ltd. (Pukesha)
4.5 Jiangsu Sinobiopharma Co., Ltd. (Yipaiping)
5 Prospect of Chinese Apixaban drug Market, 2021-2025
5.1 Influential Factors of Chinese Apixaban Market Development
5.1.1 The Impact of COVID-19 on Chinese Apixaban Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend
For more information about this report visit https://www.researchandmarkets.com/r/9jhfhr